These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 16523921

  • 1. [IgA nephropathy--pathogenesis, pathophysiology, and therapy].
    Narita I, Goto S, Kondo D, Sakatsume M, Gejyo F.
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():397-402. PubMed ID: 16523921
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Modulating the progression in IgA nephropathy.
    Chan JC, Trachtman H.
    Nephron Clin Pract; 2006 Feb; 104(1):c61-8. PubMed ID: 16741372
    [Abstract] [Full Text] [Related]

  • 4. IgA nephropathy treatment 25 years on: can we halt progression? The evidence base.
    Ballardie FW.
    Nephrol Dial Transplant; 2004 May; 19(5):1041-6. PubMed ID: 15102965
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. IgA nephropathy.
    Wardle EN.
    N Engl J Med; 2003 Jan 02; 348(1):79-81; author reply 79-81. PubMed ID: 12510692
    [No Abstract] [Full Text] [Related]

  • 9. [Update in primary glomerular diseases--mainly in IgA nephropathy].
    Kawamura T.
    Nihon Jinzo Gakkai Shi; 2002 Oct 02; 44(7):514-23. PubMed ID: 12476587
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Immunoglobulin A nephropathy: fish oils and beyond.
    Feehally J.
    Curr Opin Nephrol Hypertens; 1996 Sep 02; 5(5):442-6. PubMed ID: 8937814
    [Abstract] [Full Text] [Related]

  • 12. The CARI guidelines. Prevention of progression of kidney disease.
    Harris D, Thomas M, Johnson D, Nicholls K, Gillin A, Caring for Australasians with Renal Impairment (CARI).
    Nephrology (Carlton); 2006 Apr 02; 11 Suppl 1():S2-197. PubMed ID: 16684077
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
    Locatelli F, Vecchio LD, Pozzi C.
    Nat Clin Pract Nephrol; 2006 Jan 02; 2(1):24-31. PubMed ID: 16932386
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Therapy of patients with IgA-nephropathy: a critical appraisal.
    Floege J, Mertens P.
    Kidney Blood Press Res; 2000 Jan 02; 23(3-5):207-9. PubMed ID: 11031723
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.